Memantine — research review 1

...and that brings us to memantine, an NMDA antagonist often used to manage chronic pain. It's an interesting case because, while pain itself can definitely impact aging, there are questions about memantine’s long-term effects on biological aging and all-cause mortality.

Exactly. The evidence suggests unrelieved pain, like diabetic neuropathy, accelerates epigenetic aging and telomere shortening. A study in GeroScience in 2025, for example, PMID 39847262, found painful diabetic neuropathy was linked to accelerated epigenetic aging compared to painless neuropathy. So, treating pain is crucial.

Right. But then we weigh that against what we know, and don't know, about memantine's long-term use. While it can offer significant relief for some, particularly in supervised settings for specific conditions, its direct impact on slowing or accelerating biological aging markers or affecting all-cause mortality in the general population isn't established.

That’s key. There isn't robust evidence to suggest memantine slows biological aging or reduces all-cause mortality. And like any medication, it has potential side effects, including dizziness, confusion, and falls, particularly in older adults, which could indirectly affect quality of life and even mortality risk.

So, for individuals with chronic pain, the decision to use memantine involves carefully balancing the known benefits of pain relief against these potential long-term uncertainties and specific side effect risks. It’s a personalized medical decision, always with a healthcare provider. We're talking about the scientific landscape here, not individual medical advice.

Absolutely. The research on its direct role in biological aging beyond pain relief is still very much an open question, and definitely not a reason to stop a prescribed treatment without medical consultation.